By Fineline Cube 
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its strategic collaboration with US giant Pfizer Inc. (NYSE: PFE). The partnership aims to jointly develop a next-generation molecular simulation platform for drug discovery.
Collaboration Goals
The collaboration seeks to integrate advanced physics-based algorithms with cutting-edge AI models. This combination is designed to significantly enhance the platform’s efficiency, accuracy, and coverage of chemical space, thereby accelerating the process of small-molecule drug discovery and development.
Platform Development
The teams will focus on developing more accurate predictive models tailored to Pfizer’s proprietary chemical space. The platform will be extended to broader use cases in small-molecule drug R&D.
Xtalpi’s Role
Xtalpi will deploy its proprietary XFEP platform for Pfizer, offering comprehensive support from parameter customization to FEP calculations.-Fineline Info & Tech